Shots:The US FDA has approved IND application of IBI3032 to initiate P-I trial for cardiometabolic disordersThe P-I trials will be initiated simultaneously in China & the US, with dosing in healthy & overweight or obese participants anticipated to start in H2’25IBI3032, an oral GLP-1 receptor agonist biased toward the cAMP pathway, showed…
